CY1109510T1 - Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακων - Google Patents
Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακωνInfo
- Publication number
- CY1109510T1 CY1109510T1 CY20091101109T CY091101109T CY1109510T1 CY 1109510 T1 CY1109510 T1 CY 1109510T1 CY 20091101109 T CY20091101109 T CY 20091101109T CY 091101109 T CY091101109 T CY 091101109T CY 1109510 T1 CY1109510 T1 CY 1109510T1
- Authority
- CY
- Cyprus
- Prior art keywords
- production
- cgrp
- medicines
- toy
- selected competitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
Abstract
Αντικείμενο της παρούσας εφεύρεσης είναι οι ανταγωνιστές του CGRP του γενικού τύπου (I), στον οποίο τα A, Χ, D, Ε, G, Μ, Q και R1 έως R3 ορίζονται όπως στην αξίωση 1, τα ταυτομερή τους, τα ισομερή τους, τα διαστερεοϊσομερή τους, τα εναντιομερή τους, οι ένυδρες ενώσεις τους, τα μείγματα τους και τα άλατά τους, καθώς και τα ένυδρα άλατα τους, ιδιαιτέρως τα φυσιολογικά αποδεκτά άλατά τους με ανόργανα ή οργανικά οξέα, φάρμακα που περιέχουν τις ενώσεις αυτές, η χρήση τους και μέθοδος για την παραγωγή τους.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004015723A DE102004015723A1 (de) | 2004-03-29 | 2004-03-29 | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP05741783A EP1732917B8 (de) | 2004-03-29 | 2005-03-23 | Ausgewahlte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109510T1 true CY1109510T1 (el) | 2014-08-13 |
Family
ID=34967621
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100128T CY1108744T1 (el) | 2004-03-29 | 2009-02-04 | 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp |
CY20091101109T CY1109510T1 (el) | 2004-03-29 | 2009-10-26 | Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακων |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100128T CY1108744T1 (el) | 2004-03-29 | 2009-02-04 | 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp |
Country Status (32)
Country | Link |
---|---|
US (3) | US7479488B2 (el) |
EP (2) | EP1732917B8 (el) |
JP (2) | JP4796567B2 (el) |
KR (1) | KR20070007867A (el) |
CN (1) | CN1976916A (el) |
AR (2) | AR049625A1 (el) |
AT (2) | ATE437868T1 (el) |
AU (1) | AU2005225539A1 (el) |
BR (2) | BRPI0509368A (el) |
CA (1) | CA2558889A1 (el) |
CY (2) | CY1108744T1 (el) |
DE (2) | DE102004015723A1 (el) |
DK (1) | DK1732917T3 (el) |
EA (1) | EA012111B1 (el) |
EC (1) | ECSP066898A (el) |
ES (1) | ES2330865T3 (el) |
HR (1) | HRP20090457T1 (el) |
IL (2) | IL178334A0 (el) |
MX (1) | MX2007011526A (el) |
MY (1) | MY141754A (el) |
NO (1) | NO20064166L (el) |
NZ (2) | NZ550774A (el) |
PE (2) | PE20091884A1 (el) |
PL (1) | PL1732917T3 (el) |
PT (1) | PT1732917E (el) |
RS (1) | RS51150B (el) |
SI (1) | SI1732917T1 (el) |
TW (1) | TW200602338A (el) |
UA (1) | UA88163C2 (el) |
UY (1) | UY29437A1 (el) |
WO (1) | WO2005092880A1 (el) |
ZA (2) | ZA200606056B (el) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
AU2003237255B8 (en) * | 2002-06-05 | 2010-01-07 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004019492A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
DE102004063752A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
DE102004063753A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7439237B2 (en) * | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
EP1770086A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005050892A1 (de) * | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
SI2380592T1 (en) | 2005-11-14 | 2018-06-29 | Teva Pharmaceuticals International Gmbh | The antibody to the calcitonin-related peptide antagonist |
DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
MX2008015562A (es) * | 2006-06-08 | 2008-12-17 | Boehringer Ingelheim Int | Tratamiento de trastornos gastrointestinales con antagonistas de cgrp. |
DE102006039038A1 (de) * | 2006-08-19 | 2008-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellungsverfahren |
US7662057B2 (en) * | 2007-06-08 | 2010-02-16 | Schaeffler Kg | Eccentric tensioning device |
DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
JP5745861B2 (ja) * | 2008-03-04 | 2015-07-08 | ファイザー・リミテッドPfizer Limited | 炎症性疼痛を治療する方法 |
CN101959528A (zh) | 2008-03-04 | 2011-01-26 | 辉瑞有限公司 | 治疗慢性疼痛的方法 |
EP3165236B1 (en) | 2009-08-28 | 2022-03-16 | Teva Pharmaceuticals International GmbH | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
BR112013029959A8 (pt) | 2011-05-20 | 2021-09-08 | Alderbio Holdings Llc | Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante |
AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
HUE044062T2 (hu) | 2011-05-20 | 2019-09-30 | Alderbio Holdings Llc | Anti-CGRP készítmények és alkalmazásuk |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
PE20220337A1 (es) | 2014-03-21 | 2022-03-14 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
SG11202106766SA (en) | 2019-01-08 | 2021-07-29 | H Lundbeck As | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
JP2024509165A (ja) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | 片頭痛の治療及び/又は発生の低減 |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW209870B (el) | 1990-01-18 | 1993-07-21 | Pfizer | |
US5442044A (en) | 1991-01-04 | 1995-08-15 | Pfizer Inc. | Orally active renin inhibitors |
WO1993025574A1 (en) | 1992-06-12 | 1993-12-23 | Pfizer Inc. | Inhibitors of angiotensin i chymase(s) including human heart chymase |
US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
CA2253934A1 (en) | 1996-05-22 | 1997-11-27 | Warner-Lambert Company | Inhibitors of protein farnesyl transferase |
US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
IL127194A0 (en) | 1996-08-22 | 1999-09-22 | Warner Lambert Co | Non-peptide bombesin receptor antagonists |
EE04375B1 (et) | 1996-09-10 | 2004-10-15 | Dr. Karl Thomae Gmbh | Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod |
US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
EP1117662A1 (en) | 1998-09-30 | 2001-07-25 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
DE19937304C2 (de) | 1999-08-10 | 2003-08-21 | Boehringer Ingelheim Pharma | Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
DE10206770A1 (de) | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
DE10211770A1 (de) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US7026312B2 (en) | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
AU2003237255B8 (en) | 2002-06-05 | 2010-01-07 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US20040076587A1 (en) | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
DE10227294A1 (de) | 2002-06-19 | 2004-01-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
DE10250080A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10300973A1 (de) | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
WO2005084672A1 (de) | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US20050282857A1 (en) | 2004-04-15 | 2005-12-22 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018796A1 (de) | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004063752A1 (de) | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
DE102004063755A1 (de) | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
DE102004063753A1 (de) | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
CN101146799A (zh) * | 2005-03-23 | 2008-03-19 | 贝林格尔·英格海姆国际有限公司 | Cgrp拮抗剂、其制备方法以及其作为药物的用途 |
US7491717B2 (en) | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP1770086A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005050892A1 (de) | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
-
2004
- 2004-03-29 DE DE102004015723A patent/DE102004015723A1/de not_active Withdrawn
-
2005
- 2005-03-23 DE DE502005007786T patent/DE502005007786D1/de active Active
- 2005-03-23 PL PL05741783T patent/PL1732917T3/pl unknown
- 2005-03-23 PT PT05741783T patent/PT1732917E/pt unknown
- 2005-03-23 JP JP2007505453A patent/JP4796567B2/ja not_active Expired - Fee Related
- 2005-03-23 EP EP05741783A patent/EP1732917B8/de active Active
- 2005-03-23 PE PE2009001130A patent/PE20091884A1/es not_active Application Discontinuation
- 2005-03-23 KR KR1020067022593A patent/KR20070007867A/ko not_active Application Discontinuation
- 2005-03-23 AT AT05741783T patent/ATE437868T1/de active
- 2005-03-23 UA UAA200611256A patent/UA88163C2/ru unknown
- 2005-03-23 AU AU2005225539A patent/AU2005225539A1/en not_active Abandoned
- 2005-03-23 EP EP09160781A patent/EP2108648A1/de not_active Withdrawn
- 2005-03-23 NZ NZ550774A patent/NZ550774A/en unknown
- 2005-03-23 WO PCT/EP2005/003094 patent/WO2005092880A1/de active Application Filing
- 2005-03-23 BR BRPI0509368-6A patent/BRPI0509368A/pt not_active IP Right Cessation
- 2005-03-23 ES ES05741783T patent/ES2330865T3/es active Active
- 2005-03-23 RS RSP-2009/0374A patent/RS51150B/sr unknown
- 2005-03-23 CN CNA2005800175452A patent/CN1976916A/zh active Pending
- 2005-03-23 PE PE2005000336A patent/PE20060150A1/es not_active Application Discontinuation
- 2005-03-23 DK DK05741783T patent/DK1732917T3/da active
- 2005-03-23 AR ARP050101139A patent/AR049625A1/es unknown
- 2005-03-23 SI SI200530817T patent/SI1732917T1/sl unknown
- 2005-03-23 EA EA200601621A patent/EA012111B1/ru not_active IP Right Cessation
- 2005-03-23 CA CA002558889A patent/CA2558889A1/en not_active Abandoned
- 2005-03-25 MY MYPI20051328A patent/MY141754A/en unknown
- 2005-03-28 TW TW094109570A patent/TW200602338A/zh unknown
- 2005-03-29 US US11/093,834 patent/US7479488B2/en active Active
-
2006
- 2006-03-21 NZ NZ562537A patent/NZ562537A/en not_active IP Right Cessation
- 2006-03-21 BR BRPI0608929-1A patent/BRPI0608929A2/pt not_active IP Right Cessation
- 2006-03-21 MX MX2007011526A patent/MX2007011526A/es active IP Right Grant
- 2006-03-21 AT AT06723571T patent/ATE414074T1/de active
- 2006-03-22 AR ARP060101117A patent/AR053344A1/es unknown
- 2006-03-22 UY UY29437A patent/UY29437A1/es not_active Application Discontinuation
- 2006-07-21 ZA ZA200606056A patent/ZA200606056B/xx unknown
- 2006-09-14 NO NO20064166A patent/NO20064166L/no not_active Application Discontinuation
- 2006-09-27 IL IL178334A patent/IL178334A0/en unknown
- 2006-09-29 EC EC2006006898A patent/ECSP066898A/es unknown
-
2007
- 2007-07-18 ZA ZA200705879A patent/ZA200705879B/xx unknown
- 2007-09-20 IL IL186089A patent/IL186089A0/en unknown
-
2008
- 2008-04-07 JP JP2008099425A patent/JP2008189689A/ja not_active Withdrawn
- 2008-10-06 US US12/246,067 patent/US7700598B2/en active Active
-
2009
- 2009-02-04 CY CY20091100128T patent/CY1108744T1/el unknown
- 2009-08-25 HR HR20090457T patent/HRP20090457T1/hr unknown
- 2009-10-26 CY CY20091101109T patent/CY1109510T1/el unknown
-
2010
- 2010-02-25 US US12/712,801 patent/US20100249114A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109510T1 (el) | Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακων | |
UY28040A1 (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos. | |
UY28848A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos | |
UY28859A1 (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento | |
CY1105797T1 (el) | Ν-αρυλ-2-οχαζολιδινονο-5-καρβοξαμιδια και παραγωγα αυτων και χρηση αυτων σαν αντιβιοτικα | |
ECSP055747A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
UY28773A1 (es) | Nuevas amidas de ácidos carboxílicos, su preparación y su uso como medicamentos. | |
CY1110956T1 (el) | Παραγωγα πυριδο-πυραζινης χρησιμα ως ζιζανιοκτονες ενωσεις | |
CY1105734T1 (el) | Nεα προ-φαρμακα του 1-μεθυλο-2-(4-αμιδινοφαινυλαμινομεθυλο)-βενζιμιδαζολ-5-υλιο-καρβοξυλικο οξυ-(ν-2-πυριδυλο-ν-2-υδροξυκαρβονυλαιθυλο)-αμιδιου, η παρασκευη και η χρησιμοποιηση τους ως φαρμακων | |
CY1112921T1 (el) | Ενεργοποιητες γλυκοκινασης πυρρολιδινονης | |
CY1111627T1 (el) | Υποκατεστημενα γλυκιναμιδια με αντιθρομβωτικη δραση και ανασταλτικη δραση στον παραγοντα χα | |
ECSP088367A (es) | Derivados de bifenilo y su uso en el tratamiento de la hepatitis c | |
CY1112298T1 (el) | Ενωσεις και μεθοδοι για ρυθμιση fxr | |
CY1112377T1 (el) | Μεθοδος και συνθεσεις για τη θεραπευτικη aντιμετωπιση των αιματολογικων κακοηθειων | |
ATE372767T1 (de) | Dpp-iv-hemmer | |
PE20040636A1 (es) | Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina | |
CY1106509T1 (el) | Αμιδοακετονιτριλια κατα των παρασιτων του εντερου | |
UY30115A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica | |
CY1108267T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
CY1114130T1 (el) | Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης | |
NO20070089L (no) | DPP-IV inhibitorer | |
CY1111705T1 (el) | Παραγωγα 2-αζα-δικυκλο[3.1.0]εξανιου ως ανταγωνιστες του υποδοχεα ορεξινης | |
ECSP088184A (es) | Derivados de benzoquinazolina y su uso en el tratamiento de enfermedades óseas | |
WO2009065920A3 (de) | Verbindungen | |
CL2003002665A1 (es) | COMPUESTOS DERIVADOS DE ACIDOS CARBOXILICOS, SUS SALES; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DONDE ES NECESARIO UN INHIBIDORE DEL FACTOR Xa Y /O UN INHIBIDOR DE SERINA PROTEASA. |